semaj83/ctmatch_classification huggingface dataset:
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Influenza Influenza Vaccines Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study A male or female between, and including, 18 and 60 years of age at the time of the first vaccination Written informed consent obtained from the subject Healthy subjects as established by medical history and clinical examination before entering into the study If the subject is female, she must be of non-childbearing potential; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to first vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series  Administration of licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study History of vaccination with investigational influenza pandemic vaccine History of administration of an experimental/licensed vaccine Planned administration of a vaccine not foreseen by the study protocol during the following periods: from Day 0 up to Day 51; from 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to Month 6 and Month 12; from Month 6 up to Month 6 + 30 days; from Month 12 up to Month 12 + 30 days Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first administration of the candidate vaccines Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination History of hypersensitivity to vaccines History of allergic disease or reactions likely to be exacerbated by any component of the vaccine History of chronic alcohol consumption and/or drug abuse Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Intermittent Claudication Patient with stable symptoms of intermittent claudication of the lower extremities, secondary to chronic occlusive arterial disease from atherosclerosis etiology (symptoms present for 6 months or longer and not significantly changed within the past 3 months) Initial claudication distance of 30 to 250 meters at screening constant workload treadmill test Confirmation of underlying Peripheral Arterial Disease (PAD) at screening Confirmation of symptom stability at randomization based on constant workload treadmill test performance The patient must have optimal cardiovascular risk prevention and appropriate management of PAD, including clopidogrel at the dose of 75mg per day, during the study period  Patient participated in investigational clinical trials in the last month prior to screening Pregnant or breast-feeding woman or woman without documented double birth control measures for at least 3 months prior to randomization Symptoms of PAD before the age of 40 years Recent initiations or discontinuation of treatment by vasoactive agents (e.g., pentoxifylline, berprost sodium, papverine, isoxsuprine, nylidrin, cyclandelate, and niacin derivatives). Patients treated by cilostazol within 3 months prior to screening will also be excluded Recent lower-extremity surgical or endovascular arterial reconstructions or sympathectomy, or recent deep venous thrombosis Recent occurrence of at least one of the following: acute myocardial infarction, unstable angina, coronary artery bypass graft, percutaenous coronary intervention, transient ischemic attack or stroke The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Influenza Influenza Vaccines Subjects who the investigator believes that they can and will comply with the requirements of the protocol A male or female between, and including, 18 and 60 years of age at the time of the first vaccination Written informed consent obtained from the subject Healthy subjects as established by medical history and clinical examination before entering into the study If the subject is female, she must be of non-childbearing potential; or, if of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after completion of the vaccination series  Administration of any licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study Planned administration of a vaccine not foreseen by the study protocol during the following periods: from Day 0 up to Day 51, 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to Month 6; from Month 6 up to Month 6 + 30 days (or Month 6 + 51 days for the control groups) Previous vaccination with a pandemic candidate vaccine or a vaccine containing the same adjuvant as the study vaccine Previous proven contact with H5N1 wild type virus (i.e. contact with an individual with laboratory-confirmed H5N1 infection, or contact with an animal (e.g. poultry) which died as a result of H5N1 infection) Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first administration of the candidate vaccines Any confirmed or suspected immunosuppressive or immunodeficient condition, or autoimmune diseases such as Guillain Barre Syndrome, based on medical history and physical examination (no laboratory testing required) History of hypersensitivity to vaccines History of allergic disease or reactions likely to be exacerbated by any component of the vaccine History of chronic alcohol consumption and/or drug abuse Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Pandemic Influenza Influenza A Virus Infection Orthomyxoviridae Infections Aged 18 to 40 years on day of Informed consent form signed Able to attend all scheduled visits and to comply with all trial procedures For a woman, inability to bear a child or negative urine pregnancy test  Participation in another clinical trial in the 4 weeks preceding the first trial vaccination Planned participation in another clinical trial during the present trial period Previous participation in a clinical trial involving an investigational flu pandemic vaccine Vaccination with an influenza vaccine during the past 6 months Any vaccination in the 4 weeks preceding the first trial vaccination Vaccination planned in the 4 weeks following any trial vaccination Breast-feeding For a woman of child-bearing potential, the absence of an effective method of contraception or abstinence non observed for at least 4 weeks prior to the first vaccination and at least 4 weeks after the last vaccination Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy Known human immunodeficiency virus (HIV), hepatitis B (AgHBs) or hepatitis C seropositivity
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.25-15.0,  Wheezing age 3 months to 16 years hospitalization for expiratory wheezing written informed consent from the parents  Any chronic disease (other than allergy or asthma), e.g. heart disease, immune deficiency, or diabetes varicella and exposure to varicella if not previously have had it Systemic glucocorticoid 4 weeks prios to the study Severe disease that needs treatment in the intensive care unit or oxygen saturation below 92% despite of additional oxygen and frequent salbutamol inhalations
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vaccination No contraindications to vaccination as specified in the "Green Book" Immunisation Against Infectious Disease, HMSO Written informed consent  Known or suspected pregnancy
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-49.0,  Influenza Virus Diseases Good general health Available for the duration of the trial Willing to use acceptable forms of contraception for the duration of the study  Clinically significant neurologic, heart, lung, liver, rheumatologic, autoimmune, or kidney disease Behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may affect study participation Previously enrolled in an H7N3 influenza vaccine trial or in any study of an avian influenza vaccine Seropositive to the H7N3 influenza A virus (serum hemagglutination inhibition [HI] titer greater than 1:8) Illegal drug use or dependency determined by urine test Medical, work, or family problems as a result of alcohol or illicit drug use within 12 months prior to study entry History of severe allergic reaction Allergy to oseltamivir Asthma or reactive airways disease within 2 years prior to study entry History of Guillain-Barre syndrome
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.5-17.0,  Prophylaxis of Avian Influenza Healthy subjects  Receipt of Seasonal Influenza Vaccine for season 2007/2008 Receipt of another vaccine within 3 weeks before and after each vaccination Previous vaccination with a pandemic candidate vaccine and/or vaccine containing the adjuvant MF59 or a similar adjuvant Children who are in the local recommendation for influenza vaccination due to underlying diseases
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Influenza Influenza, Human A male or female aged 18-60 years old at the time of vaccination, who previously participated in 108656 clinical trial Subjects who the investigator believes that they can and will comply with the requirements of the protocol Written informed consent obtained from the subject Free of obvious health problems as established by medical history and clinical examination before entering into the study If the subject is female, she must be of non-childbearing potential or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series  Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the administration of the study vaccine, or planned use during the study period Planned administration of an influenza vaccine other than the study vaccines during the entire study period Previous vaccination against influenza since January 2007 Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests Chronic administration of immunosuppressants or other immune-modifying drugs within three months prior to the first vaccine dose Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination Administration of immunoglobulins and/or any blood products within three months preceding the dose of study vaccine or planned administration during the study period History of hypersensitivity to a previous dose of influenza vaccine History of confirmed influenza infection within the last 12 months Pregnancy
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Depression Pregnant woman between 18 and 40 years of age Have depression as their only mental health disorder Have been receiving fluoxetine or citalopram for the treatment of depression for at least one month on the day of study entry for patients in the fluoxetine and citalopram arms, or no pharmacological treatment for patients in the control arm ≤ 26 weeks pregnant by estimated date of confinement Ability to give informed consent Singleton pregnancy Pregnant women no history of depression  Having any comorbid mental disorder other than generalized anxiety disorder as a secondary disorder History of or current epilepsy, endocrine, cardiac, pulmonary, renal or hepatic dysfunction that could negatively influence pregnancy and/or neonatal outcome Abusing alcohol or drugs Use of any self prescribed herbal treatments for depression
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 35.0-999.0,  Hypertension Baseline SBP 130-159 mmHg (+/ mHg) or DBP 85-99 mmHg (+/ mm Hg) 2. Age 35 years or older 3. BMI 25.0-39.99 kg/m², with a maximum weight of 300 lbs 4. Willing and able to participate fully in all aspects of the intervention 5. Must currently be sedentary (less than 3x/wk for 30 mins each time) 6. Informed consent  Use of weight-loss medication and/or participation in a structured weight loss program in the 3 months prior to 1st screening visit. 2. Regular use of an anti-hypertensive drug or other drugs that raise or lower BP and if discontinued use, must be off for 1 month before screening 3. Current use of insulin or oral hypoglycemic agents 4. Current use of medications for treatment of psychosis or manic-depressive illness. 5. ADHD medications (Ritalin/Aderol/amphetamines 6. Cardiovascular Event 7. Coronary Artery Disease 8. Congestive Heart Failure 9. Current symptoms of Angina for peripheral vascular disease 10. Cancer diagnosis (except for non-melanoma skin cancer) or treatment in past 2 years 11. Fasting blood sugar >126 mg/dl 12. Gastric Bypass/Bariatric Surgery 13. Pyschiatric hospitalization in the past 2 years. 14. Unable or willing to consume all of the dietary foods provided during the 2-week feeding. 15. Consumption of more than 21 alcoholic drinks per week or binge drinking 16. Alcoholism as determined by the Alcohol AUDIT (screening questionnaires) 17. Planning to leave the area prior to the anticipated end of participation 18. Body weight change of >15lbs in the 3 months prior to the 1st screening visit 19. Pregnant, breast feeding, or planning pregnancy prior to end of participation 20. Current participation in another clinical trial until after completion of T2 21. Investigator discretion for safety or adherence reasons 22. Controlled substance abuse
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cystic Fibrosis Constipation Nutrition Planning or currently on chronic lubiprostone therapy (chronic is defined as at least one 24 microgram capsule by mouth every other day Body mass index (BMI) of less than 22 for females and less than 23 for males at the initiation of chronic lubiprostone therapy Initiation of chronic lubiprostone therapy within 1 month of enrollment Age over 18 Currently taking a multivitamin  History of noncompliance with medications and other CF therapies History of hospital admissions for CF exacerbations of ≥2 in the last 6 months FEV1 les than 40% of expected (severe dysfunction) at most recent assessment in the ambulatory setting Currently registered on a lung transplant waiting list Any other condition, in the opinion of the investigators, that interferes with the ability of the study subject to comply with study requirements, confers significant risk, or limits the ability of the subject to complete the study
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Chronic Lymphocytic Leukemia Untreated stage A CLL patients Healthy volunteers  Patients with other malignancies Patients receiving corticosteroids or other immunosuppressive drugs Patients who have received vaccination against influenza in the past 6 months Patients who have had an allergic reaction to a flu shot in the past, or have an allergy to eggs or who previously developed Guillain-Barré syndrome within 6 weeks of getting a flu shot Patients failing to give informed consent Patients using homeopathic remedies such as echniaea cream
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-1.0,  Childhood Immunization Completion Childhood Immunization Dropout Immunization Card Center Based Education All children visiting the selected EPI centers for DPT1 immunization  Not residing in the same area for last six months
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 3.0-5.0,  Healthy 5 year old children Full term at birth English as primary language Weighed at least 5.5# at birth Parent or guardian is at least 18 years of age  Child has any chronic condition, metabolic disorder, pulmonary disorder, bone disorder, condition that may affect growth, ADD or ADHD Child on any medication thought to interfere with study parameters as determined by the investigator